Claims for Patent: 8,563,527

Summary for Patent: 8,563,527

Title:	Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
Abstract:	The present invention relates, in part, to an oligonucleotide-core carrier comprising a carrier, and oligonucleotide groups covalently linked to the carrier. The oligonucleotide groups are capable of dissociably linking load molecules such as therapeutic agents. The oligonucleotide-core carrier may also comprise protective side chains, and targeting molecules.
Inventor(s):	Castillo; Gerardo M. (Bothell, WA), Bolotin; Elijah M. (Bothell, WA), Bogdanov, Jr.; Alexei A. (Westborough, MA)
Assignee:	Pharmain Corporation (Bothell, WA)
Application Number:	12/194,144
Patent Claims:	1. An oligonucleotide-core carrier composition comprising: (i) a carrier; (ii) at least one of a first single stranded oligonucleotide group covalently linked to the carrier, wherein the oligonucleotide group is less than 100 bases; (iii) a plurality of polymeric protective side chains, wherein each protective side chain is covalently linked and pendant to the carrier and/or to the first oligonucleotide group wherein each protective side chain has a molecular weight between about 400 and 20,000 Daltons independent of the carrier weight and the first oligonucleotide group weight; and (iv) a load molecule, wherein the load molecule comprises a peptide/protein covalently bonded to a second single stranded oligonucleotide group with an essentially complementary sequence to the first single stranded oligonucleotide group and dissociably linked by nucleotide hydrogen bonding base pairing to the first oligonucleotide group; wherein said carrier is a polymer selected from the group consisting of a polyamino acid, a polyethyleneimine, a polyallyamine, a chitosan, a polysaccharide, an oligosaccharide, a natural saccharide, an aminated and carboxylated polysaccharide, an aminated and carboxylated oligosaccharide, a sulfonated polysaccharide, a sulfonated oligosaccharide, an aminocarboxylated polysaccharide, an aminocarboxylated oligosaccharide, a carboxymethylated polysaccharide, a carboxymethylated oligosaccharide, a polyamidoamine, a polyacrylic acid, a polyvinyl alcohol, and a polythiol; and further wherein the plurality of polymeric protective side chains comprises polyethylene glycol, polypropylene glycol, or a co-polymer of polyethylene glycol and polypropylene glycol. 2. The oligonucleotide-core carrier composition of claim 1, wherein the first oligonucleotide group comprises various nucleotide monomers selected from the group of monomers consisting of deoxyribonucleotide, 2'-deoxyribonucleotide, ribonucleotide, 2'-O-methylribonucleotide, locked ribonucleotide, N-(2-ethylamino)glycine nucleotide and morpholino nucleotide, wherein each nucleotide is covalently linked to another by a 3'-5' or 2'-5' linkage, wherein the linkage comprises a phosphodiester, phosphorothio, phosphotriester, phosphorodiamidate or a peptide, and wherein the base component of the nucleotide is any one of adenine, thymine, guanine, cytosine, uracil, inosine, thioinosine, thiouridine, xanthosine, pseudouridine, or orotidine. 3. The oligonucleotide-core carrier composition of claim 1, wherein the load molecule is a therapeutic agent. 4. The oligonucleotide-core carrier composition of claim 3, wherein the therapeutic agent is oligonucleotide-bonded peptide/proteins; wherein the peptide/protein is selected from a group consisting of a peptide aptamer, a glucagon-like peptide, a glucagon-like-peptide derivative, exenatide, leptin, a leptin fragment, alpha melanocyte stimulating hormone, adeponectin, Gastric inhibitory polypeptide(GIP), an Epidermal Growth Factor (EGF) receptor ligand, EGF, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, a Gastrin/Cholecystokinin receptor ligand, Gastrin, Cholecystokinin, lysostaphin, interferon, interferon gamma, interferon beta, interferon alpha, interleukin-1, interleukin-2, interleukin-4, interleukin-6, interleukin-8, interleukin-10, interleukin-12, tumor necrosis factor, tumor necrosis factor alpha, tumor necrosis factor beta, insulin, insulin-like growth factor, growth hormone, nerve growth factor, brain-derived neurotrophic factor, enzymes, endostatin, angiostatin, trombospondin, urokinase, streptokinase, blood clotting factor VII, blood clotting factor VIII, granulucyte-macrophage colony-stimulating factor (GMCSF), granulucyte colony-stimulating factor (G-CSF), thrombopoetin, calcitonin, parathyroid hormone (PTH) and its fragments, erythropoietin, atrial natriuretic factor, monoclonal antibodies, monoclonal antibody fragments, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone-releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, and filgrastin. 5. The oligonucleotide-core carrier composition of claim 3, wherein the therapeutic agent is oligonucleotide-bonded peptide/proteins; wherein the peptide/protein is selected from a group consisting of Glucagon-like-peptide, Leptin, a Leptin fragment, Peptide YY, an Epidermal Growth Factor (EGF) receptor ligand, EGF, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, a Gastrin/Cholecystokinin receptor ligand, Gastrin, Cholecystokinin, interferon, factor VIII, terlipressin, Gastric inhibitory polypeptide(GIP), and vasoactive intestinal peptide (VIP). 6. The oligonucleotide-core carrier composition of claim 1, further comprising a targeting molecule covalently linked to at least one protective side chain. 7. The oligonucleotide-core carrier composition of claim 6, wherein the targeting molecule is selected from the group consisting of antibodies, fragments of antibodies, chimeric antibodies, lectins, receptor ligands, proteins, enzymes, peptides, saccharides, quasi substrates of enzymes, cell-surface-binding compounds, and extracellular-matrix-binding compounds. 8. The composition of claim 2, wherein the first oligonucleotide group comprises a deoxyribonucleotide monomer. 9. The composition of claim 1, wherein the carrier is 2,000 to 60,000 Daltons. 10. The composition of claim 1, wherein the first single stranded oligonucleotide group is guanine rich and the second single stranded oligonucleotide group is cytosine rich. 11. The composition of claim 1, wherein the first single stranded oligonucleotide group is cytosine rich and the second single stranded oligonucleotide group is guanine rich. 12. The composition of claim 1, wherein the first single stranded oligonucleotide group is adenine rich and the second single stranded oligonucleotide group is thymine rich. 13. The composition of claim 1, wherein the first single stranded oligonucleotide group is thymine rich and the second single stranded oligonucleotide group is adenine rich. 14. A method of increasing the blood circulation half-life of peripherally administered peptide/protein covalently bonded to single stranded oligonucleotide by injecting into a patient a formulation comprising the oligonucleotide-core carrier composition of claim 1. 15. The method of claim 14, wherein the peptide/protein covalently bonded to single stranded oligonucleotide is selected from a group consisting of a peptide, an enzyme, an antibody, and a cytokine. 16. The method of claim 15, wherein the cytokine is an interferon or a tumor necrosis factor. 17. The method of claim 15, wherein the antibody is selected from the group consisting of a monoclonal antibody, an antibody fragment, and a chimeric antibody. 18. The method of claim 14, wherein the peptide/protein covalently bonded to single stranded oligonucleotide is selected from a group consisting of a peptide aptamer, a glucagon-like peptide (GLP), a glucagon-like-peptide derivative, exenatide, leptin, a leptin fragment, alpha melanocyte stimulating hormone, adeponectin, Gastric inhibitory polypeptide(GIP), an Epidermal Growth Factor (EGF) receptor ligand, EGF, Transforming Growth Factor alpha (TGF-alpha), Betacellulin, a Gastrin/Cholecystokinin receptor ligand, Gastrin, Cholecystokinin, lysostaphin, terlipressin, interferon, interferon gamma, interferon beta, interferon alpha, interleukin-1, interleukin-2, interleukin-4, interleukin-6, interleukin-8, interleukin-10, interleukin-12, tumor necrosis factor, tumor necrosis factor alpha, tumor necrosis factor beta, insulin, insulin-like growth factor, growth hormone, nerve growth factor, brain-derived neurotrophic factor, enzymes, endostatin, angiostatin, trombospondin, urokinase, streptokinase, blood clotting factor VII, blood clotting factor VIII, granulucyte-macrophage colony-stimulating factor (GMCSF), granulucyte colony-stimulating factor (G-CSF), Peptide YY, thrombopoetin, calcitonin, parathyroid hormone (PTH) and its fragments, erythropoietin, atrial natriuretic factor, monoclonal antibodies, monoclonal antibody fragments, chimeric antibodies, somatostatin, protease inhibitors, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, leutinizing-hormone releasing-hormone, follicle stimulating hormone, glucocerebrosidase, thrombopoietin, and filgrastin.

Details for Patent 8,563,527

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2027-08-20
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2027-08-20